Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Cash: 2014-2025

Historic Change in Cash for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $6.7 million.

  • Zevra Therapeutics' Change in Cash fell 54.48% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year decrease of 96.29%. This contributed to the annual value of -$9.3 million for FY2024, which is 58.67% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Change in Cash stood at $6.7 million, which was down 35.14% from $10.4 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Change in Cash peaked at $71.7 million during Q1 2021, and registered a low of -$25.3 million during Q1 2023.
  • For the 3-year period, Zevra Therapeutics' Change in Cash averaged around -$1.0 million, with its median value being -$200,000 (2024).
  • As far as peak fluctuations go, Zevra Therapeutics' Change in Cash spiked by 7,178.38% in 2021, and later plummeted by 9,106.36% in 2024.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Change in Cash stood at -$19.2 million in 2021, then surged by 76.02% to -$4.6 million in 2022, then spiked by 95.21% to -$220,000 in 2023, then tumbled by 9,106.36% to -$20.3 million in 2024, then crashed by 54.48% to $6.7 million in 2025.
  • Its Change in Cash stands at $6.7 million for Q3 2025, versus $10.4 million for Q2 2025 and $3.6 million for Q1 2025.